🧵 1. Wegovy, the weight loss drug from Novo Nordisk, eases heart failure symptoms in obese patients, reducing shortness of breath and fatigue. #business
🧵 1. Wegovy, the weight loss drug from Novo Nordisk, eases heart failure symptoms in obese patients, reducing shortness of breath and fatigue. #business
🧵 2. Alongside weight loss, Wegovy lowers blood pressure and inflammation, improving heart health markers. Potential for expanded use and insurance coverage.
🧵 3. Recent trial shows Wegovy reduces risk of serious heart problems by 20%. Novo Nordisk hopes to capitalize on observed heart health benefits.
🧵 4. In a study of 529 obese patients, Wegovy improves symptoms of preserved ejection fraction (HFpEF) heart condition. Nearly 17-point improvement on symptom scale compared to placebo.
🧵 5. Besides symptom improvement, those on Wegovy lost 13% of body weight, walked farther in 6 mins, and experienced fewer safety events. Gastrointestinal issues were a common side effect.
🧵 Read more at: https://www.cnbc.com/2023/08/25/wegovy-helps-reduce-heart-failure-symptoms-obese-people-study.html